Brief: Landos Biopharma Announces FDA Clearance Of Its Ind For Labp-104 For Treatment Of Systemic Lupus Erythematosus
11/10/2021 13:10
Oct 11 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA ANNOUNCES FDA CLEARANCE OF ITS IND FOR
LABP-104
FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
* LANDOS BIOPHARMA INC - PHASE 1 TRIAL INITIATION EXPECTED
BEFORE
YEAR END WITH TOPLINE RESULTS IN 1H 2022
Source text for Eikon: ID:nGNX4tzS1d
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma